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3042Objective: The short-term outcomes were evaluated in patients treated for tricuspid valve endocarditis using a
novel extracellular matrix (ECM) cylinder reconstruction technique.
Methods: Patients with clinically significant tricuspid regurgitation whose valves were not repairable by con-
ventional techniques underwent valve replacement with a cylindrical construct sewn out of CorMatrix ECM
(CorMatrix Cardiovascular, Roswell, Ga). The cylinders were sized to the native valve dimensions and attached
distally to the papillary muscles using polypropylene sutures and ECM pledgets, and proximally to the annulus
using a running suture. Patient data were collected retrospectively.
Results: FromNovember 2011 toOctober 2013, 12 surgeons performed19 tricuspid valve cylinder reconstructions
in 8 men and 10 women (age range, 19-53 years). Of the 19 patients, 11 had active and 5 had treated endocarditis.
One case was robotic-assisted. No deaths occurred, and no new cases of heart block developed. The papillary at-
tachmentswere disrupted intraoperatively in 1 patient and after 7 days in another; bothwere successfully revised.A
third patient experienced recurrent disruption of the implant at 13 and 22months and ultimately received a pericar-
dial valve. Fungal infection occurred in 1 cylinder at 6 months; a second ECM cylinder was implanted. Follow-up
data were available for 13 patients at 1 to 2 months, 8 at 6 months, and 3 at 12 and 18 months. Other than patients
undergoing reoperation, all showed well-functioning tricuspid valves with no to mild regurgitation.
Conclusions: Cylinder reconstruction with ECM could be a suitable technique for replacing the tricuspid valve
while preserving annuloventricular continuity in patients with infective endocarditis not repairable by conven-
tional techniques. (J Thorac Cardiovasc Surg 2014;148:3042-8)Isolated tricuspid valve regurgitation secondary to infective
endocarditis is most commonly associated with pacemaker
infection or intravenous drug abuse,1 and the surgical op-
tions for treating this pathologic entity are suboptimal.
Mechanical and bioprosthetic valves are subject to throm-
bosis or degenerative calcification, respectively,2-4 and no
commercially available valve prostheses are specifically
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Abbreviation and Acronym
ECM ¼ extracellular matrix
Gerdisch et al Acquired Cardiovascular Diseaseendocarditis8,9; however, materials such as poly-
tetrafluoroethylene, polyethylene terephthalate, and
glutaraldehyde-fixed pericardium are subject to a foreign
body response and degenerative calcification and reinfec-
tion.4,10,11 New tricuspid bioprostheses that use bio-
compatible materials in a more functional design are
desirable.
In the present report, we assembled the collective, initial
clinical experience of 12 independent surgeons using a
biocompatible (non-crosslinked), extracellular matrix
(ECM)-based material, fashioned into a simple tubular
valve similar to the tubular aortic valve originally pioneered
by Cox and colleagues,12 for tricuspid cylinder reconstruc-
tion in the treatment of infective endocarditis.A
C
DMETHODS
The present retrospective chart review was determined to be exempt by
the Office of Research Services at the Franciscan St Francis Health Center.
Inclusion and Exclusion Criteria
Each surgeon reviewed the medical records of the adult patients who
had undergone ECM tricuspid cylinder reconstruction from 2011 to
2013. All these patients were treated for tricuspid regurgitation secondary
to infective endocarditis, with valve pathologic features that were irrepa-
rable by conventional techniques.
Operative Preparation
The patient assessment, preparation, and the specific surgical ap-
proaches were according to surgeon preference and clinical judgment. Pre-
operative echocardiography was used to assess the extent of destruction
and to determine the native valve length and diameter. With the exception
of a single, robotic-assisted case, all surgical procedures were performed
through a median sternotomy, with the patient under general endotracheal
anesthesia, and standard cardiopulmonary bypass with bicaval cannulation.
The valves were constructed before initiating cardiopulmonary bypass.
Cylinder Construction and Implantation
To form the cylindrical replacement valve, a sheet of CorMatrix ECM
(CorMatrix Cardiovascular, Roswell, Ga) was fashioned into a cylinder
with a final diameter sized to match the native annulus. The length of the
tube was determined by either the echocardiographic distance from the
annulus to the papillary muscle tips or standardized to 120% of the cylin-
der’s diameter. The seam was sewn with a single-layer, running 4-0 or 5-
0 polypropylene suture (Prolene; Ethicon, Endo-Surgery, Somerville,
NJ), although in 1 early case (patient 2), polydioxanone suture (Ethicon)
was used (not recommended; see the Results and Discussion sections).
Most cases were performed at least partly under cardiac arrest. After
crossclamping, myocardial protection, and arrest, all infected tissue,
including when necessary, the entire tricuspid valve, partial annulus, and
chordae were resected and debrided down to healthy tissue.
For placement of the cylinder (Figures 1 and 2), 3 ventricular
attachment points were identified. Because the right ventricular papillary
muscle number and position varied, 3 papillary muscle attachments were
chosen, roughly equidistant at 120 apart. The anterior papillary muscleThe Journal of Thoracic and Carwas most consistently positioned and typically acted as the reference
point for the choice of the other attachments. The septal chordal
insertion might not be discrete, with multiple small muscular sites of
attachment. The cylinder suture line was aligned with the septal
attachment. Depending on the status of the subvalvular apparatus after
debridement and surgeon preference, the attachment was performed at
the tips, base, or body of the selected papillary muscles. The attachments
were made by placing mattress stitches (usually 4-0 or 5-0
polypropylene or polyester) with or without pledgets (CorMatrix ECM
or Teflon; DuPont, Wilmington, Del) in the tissue at each of the papillary
attachment points (Figures 1, A, and 2, A and B) and tying them down at
3 evenly spaced points along the distal edge of the ECM cylinder
(Figures 1, B, and 2, C and D).
The proximal edge of the cylinder was sutured to the annulus, using
running 4-0 or 5-0 polypropylene or polyester suture (Figures 1, C, and
2, E). For some valves, the proximal end was folded over to create a
0.5-cm double layer. The seated valves were tested for ‘‘neoleaflet’’
coaptation and competence (Figure 2, F), and the right atrium was closed.
After de-airing and weaning from bypass, valve function was confirmed
using transesophageal echocardiography before chest closure (Figure 3).
Follow-up and Data Collection
When possible, the patients were assessed by echocardiography imme-
diately postoperatively and then approximately 1, 6, 12, and 18 months
postoperatively. The medical records were reviewed to collect demo-
graphic, operative, and echocardiographic data. Because of the small num-
ber of patients, both overall and per surgeon, the patient data are presented
individually, where practical. Descriptive statistics are presented as the
mean  standard deviation and were calculated using the Microsoft Excel
program (Microsoft, Redmond, Wash).RESULTS
From November 2011 to October 2013, 19 tricuspid
valve cylinder reconstructions were performed in 18 pa-
tients by 12 surgeons. Of the 18 patients, 8 were men and
10 were women (mean age, 34.8 8.8 years; body mass in-
dex, 23.28  11.8 kg/m2).
Endocarditis was active in 11 patients, treated in 5, and
remote in 2 (9 methicillin-sensitive Staphylococcus aureus,
5 methicillin-resistant S aureus, 1 Propionibacterium
acnes, 1 poly-infection with methicillin-sensitive S aureus,
and Achromobacter). One case was a reoperation to replace
a degenerated prosthetic valve. Of the 18 patients, 16 had a
confirmed history of intravenous drug abuse. Septic emboli
were present in 14 patients (13 pulmonary, 2 systemic).
Other comorbidities and risk factors included encephalopa-
thy (n ¼ 6), renal dysfunction (n ¼ 6), mild to moderate
mitral regurgitation (n ¼ 4), hypertension (n ¼ 4), history
of previous tricuspid valve replacement (n ¼ 3), chronic
obstructive pulmonary disease (n ¼ 1), transient ischemic
attack (n ¼ 1), and patent foramen ovale (n ¼ 1).
Preoperatively, 6 patients required intravenous vasopres-
sors or inotropic support and 2 had severe right ventricular
dilation. One patient required preoperative ventilatory
support.
One case (patient 12) was performed using robotic assis-
tance (da Vinci S; Intuitive Surgical, Sunnyvale, Calif).
Concurrent procedures included 2 mitral valve repairs, 1diovascular Surgery c Volume 148, Number 6 3043
FIGURE 1. Illustration depicting extracellular matrix cylinder implantation technique. A, Mattress sutures are placed in each of the 3 papillary attachment
points. B, The extracellular matrix cylinder is tied down at 3 evenly spaced points, with the seam aligned with the septal papillary muscle. C, The proximal
edge is sutured to the annulus in a circumferential fashion.
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closure, 1 explantation of an automated implantable cardi-
overter defibrillator, 1 dialysis catheter implantation, and
1 repair of an occult right femoral hernia. The pericardium
was reconstructed with CorMatrix ECM for pericardial
closure in 6 patients.
Adverse Events
During the follow-up period, no deaths or strokes
occurred, and no new-onset patient–prosthesis mismatch
was present. Early postoperative events included pulmo-
nary embolism in 2 patients (both with preoperative history3044 The Journal of Thoracic and Cardiovascular Surof pulmonary embolism) and disseminated intravascular
coagulation with acute kidney injury requiring temporary
dialysis in 1 patient.
Structural disruptions occurred in 2 early and 1 late case.
In 1 case (patient 1), 1 polypropylene suture tore through
the papillary muscle intraoperatively, during protamine
administration. The patient was reheparinized. On direct in-
spection, it was determined that all 3 attachments had torn
through the papillary tissue. The attachments were revised
with pledgeted, braided polyester suture (TiCron; Covidien,
New Haven, Conn). In another case (patient 10), all 3 poly-
propylene attachment sutures had come untied within 7gery c December 2014
FIGURE 2. Extracellular matrix tricuspid cylinder reconstruction technique. A and B, Placement of sutures in papillary attachment points. C, Extracellular
matrix cylinder before implantation. D, The distal edge of the cylinder is tied down to the attachment points. E, The cylinder’s proximal edge is sutured
circumferentially to the annulus. F, Completed repair showing valve competence under saline insufflation.
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tachments were tied down with braided suture.
A third patient (patient 2) returned 13 months postopera-
tively with worsening tricuspid regurgitation secondary to
disruption of the cylinder seam and septal papillary attach-
ment. In this patient, polydioxanone sutures had been used
for the seam construction and implantation of the cylinder at
the first operation. The seam and attachments were revised
with polypropylene, but the regurgitation had recurred at 22
months. The cylinder was resected up to the annulus, and a
pericardial bioprosthesis was implanted.FIGURE 3. Postoperative echocardiogram showing completed valve
reconstruction and neoleaflet coaptation. RA, Right atrium; RV, right
ventricle.
The Journal of Thoracic and CarPatient 5 returned approximately 6 months postopera-
tively with a fungal infection of the cylinder. A second
ECM cylinder was placed during reoperation.
Patient adherence to the follow-up visit schedule was
relatively poor. Echocardiographic follow-up data were
successfully collected for 13 of 17 eligible patients at 1 to
2 months, 8 of 10 at 6 months, 3 of 3 at 12 months, and 3
of 3 at 18 months. Other than the patients undergoing reop-
eration as described, all showed well-functioning tricuspid
valves with no to mild regurgitation and no evidence of
tricuspid stenosis. The New York Heart Association classi-
fication had improved in all evaluated patients, and the left
and right ventricular function had remained stable or
improved during the follow-up period.DISCUSSION
The concept of a tubular prosthetic atrioventricular heart
valve was pioneered by James Cox in the late 1980s, based
on the hypothesis that native cardiac valves function as sim-
ple tubes, with sides that collapse when subjected to
external pressure.12 That work ultimately led to the devel-
opment and Food and Drug Administration clearance
of the 3F aortic bioprosthesis (Medtronic, Minneapolis,
Minn).
Cox and colleagues12 tested a number of materials,
including an early, investigational preparation of the small
intestinal submucosa ECM in the design for both the mitral
and the tricuspid positions. The studies showed that the abil-
ity of the tubular design to restore normal transprosthetic
flow dynamics and stress distribution on the valve leaflets
was not dependent on the material used for fabrication.diovascular Surgery c Volume 148, Number 6 3045
FIGURE 4. Possible placement of sutures in the tricuspid valve annulus
during cylinder reconstruction (red lines). A, Recommended placement.
At the level of the annulus, the triangle of Koch is avoided and the atrioven-
tricular node–His bundle complex is quite deep, protecting it from interfer-
ence by the sutures. B, Sutures placed along the tendon of Todaro around
the atrioventricular node or placed deeply where the bundle of His traverses
into the ventricular septum have the potential to create heart block and
should be avoided. AV, Atrioventricular.
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the material for the commercial 3F aortic valve product,
marking a necessary tradeoff between the benefits of prod-
uct durability and the known limitations of chemically fixed
tissue (ie, degenerative foreign body response, calcification,
susceptibility to infection, and the lack of somatic growth
potential).
Since then, clinical experience with ECM as a surgical
material has increased, and it has now been successfully
used in a variety of clinical applications, including aortic
annular enlargement, mitral valve repair, myocardial and
intraventricular repair, pericardial reconstruction, and
vascular repairs.13-20
In 2013, Fallon and colleagues21 published the results of
a small pilot study of the cylindrical tricuspid ECM valve in
an ovine model. From the echocardiographic results and
gross and microscopic histologic analysis, they found that
the cylindrical ECM construct was able to function as a
biomechanically sound, bioprosthetic tricuspid valve
replacement for12months, without degeneration or calci-
fication.21 Histopathologic examination of explanted con-
structs showed evidence of progressive endothelialization
and constructive tissue remodeling.3046 The Journal of Thoracic and Cardiovascular SurThe first in-human ECM tricuspid cylinder reconstruc-
tion was performed byWallen and Rao22 at Toronto General
Hospital on November 3, 2011. Early results from others’
experience with this technique had been presented at med-
ical meetings,23-25 but the present study represents the first
publication of this technique in full, with collaboration
among surgical groups distributed across North America.
Key Lessons
We noted several interesting technical insights. Although
several cases required complete excision of the septal leaflet
and/or the entire valve, no cases of heart block occurred.
This could represent a substantial advantage over standard
prosthetic valve implantation. The cylinder valve construct
is sewn circumferentially to the annulus with running su-
ture. Because the suture line does not include the conduc-
tion structures in the triangle of Koch, heart block is
avoided (Figure 4, A). Heart block could potentially be
created if a stitch were placed deep beyond the annulus,
at the point at which the bundle of His traverses into the ven-
tricular septum, but this is easily avoided (Figure 4, B).
The use of biodegradable polydioxanone suture in an
early case likely contributed to valve seam dehiscence
that ultimately necessitated replacement with a bio-
prosthetic valve. From the clinical experience and the man-
ufacturer’s recommendations, until the dynamics of ECM
degradation and remodeling are better understood relative
to the resorption of biodegradable suture materials, such su-
tures should not be used for applications in which they must
provide structural integrity in the presence of continual
biomechanical stress. Furthermore, the findings from ani-
mal histologic studies have suggested that polypropylene
sutures induce the least-intense inflammatory response
and are therefore recommended by the ECM’s manufac-
turer over other nonabsorbable sutures (CorMatrix Cardio-
vascular; data on file).
In another case, the suture pulled through the tissue
where it had been attached at the base of the papillary mus-
cles. To achieve normal inflow, attachment to the papillary
tips would be more desirable. In addition to potentially
increasing strain on the attachment, the base of the muscle
lacks the structural strength of the fibrous tip. Because the
septal muscular attachment for the chordae is frequently
relatively diffuse, the surgeon must determine it. A domi-
nant fibrous point of connection can be seen. The level of
attachment might be more proximate, requiring adjustment
of the cylinder length on that side.
A potential advantage of the cylinder construct is mainte-
nance of the annuloventricular continuity, even in cases of
total leaflet and chordal disruption. Just as is true with the
left ventricle, disconnecting the papillary muscles from
their annular connection can lead to late loss of the ventric-
ular conical shape and dilatation. Because all but 1 of the
patients in the present report had only recently developedgery c December 2014
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enlargement was found. It remains to be determined how
the dimensions of the cylinder might be altered to remain
functional and still promote restoration of ventricular geom-
etry.26 In addition, left ventricular function can affect right
ventricular papillary muscle position and, therefore, could
affect performance of the cylinder.27
Finally, the 2 cases of pulmonary embolism were in pa-
tients with recent preoperative history of embolism, and it
was difficult to determine whether ECM implantation
contributed to the postoperative recurrence of this compli-
cation. Continued long-term follow-up is necessary to
confirm that this technique does not increase the risks of
this or other serious complications.
Study Limitations
The present study was a small, retrospective, explor-
atory effort in a difficult and poorly adherent patient pop-
ulation, with heterogeneity in surgical techniques. This
procedure re-creates the structural components of the
valve but also remains dependent on the ventricular geom-
etry and annulopapillary relationship. Thus, successful im-
plantation will likely be guided by some fundamental
parameters that remain to be defined. Three of the 4 fail-
ures in the present series appeared technique related; 1
actually occurred intraoperatively, and the sharing of this
experience will help clarify the methods of addressing
these challenges.
Ultimately, our goal is to develop a technique with the
ease and reliability of implantation similar to that for cur-
rent standard replacement valves, and the functional and
biocompatibility advantages anticipated with the combina-
tion of the cylinder design with ECM. However, the long-
term success has yet to be demonstrated.
If we focus on the primary objective of the study,
which was to evaluate the overall feasibility of using a
cylindrical prosthetic valve made of bioresorbable ECM
material in the tricuspid position, we can conclude that
patients with tricuspid valve endocarditis not repairable
by conventional techniques can be successfully treated
with ECM cylinder reconstruction. This approach main-
tains the annuloventricular continuity important to long-
term ventricular function and, by virtue of biocompatibility,
it might offer improved longevity in a biologic construct.
We will continue to encourage the patients in the present
series to return for follow-up evaluation, so that we can
monitor and report on their health and progress. From the
results of the present series, a formal, prospective clinical
study is currently being planned.
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Dr Damien J. LaPar (Charlottesville, Va). Dr Gerdisch, I
would like to thank you very much for sending us the report ahead
of time and presenting a very provocative and novel concept for the
treatment of tricuspid valve endocarditis, which we all know is a
significant problem.
The authors of this report present 19 patients who underwent a
novel tricuspid valve replacement using a cylinder technique using
CorMatrix. Importantly, only 8 patients had follow-up data avail-
able at 6 months, and only 3 patients had follow-up for 1 year.
There were 3 patients who experienced failure of this de novo
valve owing to sutures pulling through the papillary muscles. We
have a few questions for you.
First, howwere your patients selected? It is not uncommon to be
able to prepare the tricuspid valve in the setting of endocarditis.
Can you tell us what the total denominator of all the patients
who underwent tricuspid valve surgery at your institutions,
including those repaired?
When did you elect to use this technique and when did you
repair, and when did you decide to perform a conventional
tricuspid valve replacement?
Dr Gerdisch. Thank you. Those are all excellent questions.
Unfortunately, I do not have information for all the institutions
with respect to how many tricuspid replacements and repairs were
performed during the same period. All the valves were deemed
irreparable by other methods. I agree that under certain circum-
stances, a tricuspid valve can well be repaired. These were all
deemed not repairable, completely destroyed valves.3048 The Journal of Thoracic and Cardiovascular SurIn regard to whether other patients received prostheses, I
cannot speak to that either. Typically, the factors that influenced
the surgeons were active infection, and, in fact, the high recidivism
with patients who were intravenous drug abusers.
Dr LaPar. Great. Thank you. My next question is more tech-
nical. The failure rate in this study was largely due to papillary
muscle rupture or sutures pulling through the annulus. In our expe-
rience at the University of Virginia, we had 1 failure due to the Pro-
lene sutures breaking at the level of the annulus on postoperative
day 1, which required a reoperation.
Why do you think this might have occurred, and are you doing
anything, particularly now, because youmentioned in your conclu-
sions that you are refining the technique, to secure the valve after
your experience here?
Dr Gerdisch. So that suture disruption was at the annulus, is
that what you said?
Dr LaPar. Yes.
DrGerdisch. That is even more unusual. We have not seen that.
I have not been aware of that actually and thank you for telling us
about it.
This, as you know, has been an attempt to accumulate the na-
tional experience. Also, you mentioned earlier that we have
limited follow-up, and it is true. One of the reasons that we decided
to press ahead with a publication was that we realized that people
were adopting, and we wanted to have a consensus idea from
everyone how they thought the application was going, what they
thought we should change about it, and also just to keep track.
As you mentioned, typically, papillary muscle disruption
seemed to be the mechanism of failure, and we, at our most recent
conversations about this, thought that perhaps there could be a
couple of mechanisms obviously. One would be that simply too
much tension is there. That limb that detaches might be too short;
that perhaps it is better to have a little bit too long than too short
when you build the cylinder. Also, it tends to be at the septal papil-
lary muscle, which frequently is not well defined and often one is
attaching to the endocardial surface of the heart, and it is more
difficult to define how deep to go and how nice a purchase you
can achieve there.
We need to continue to have those conversations. I think that
making the tube just a little bit more generous in length than short,
and also at the annulus, that is the first time we have seen that, but
trying to create an annulus of normal dimensions for the patient.
Dr LaPar. Thank you very much for this contribution.gery c December 2014
